A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes

Trial Profile

A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary) ; Azacitidine; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to lack of funding to support clinical trial.
    • 20 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top